Kyongbo Pharmaceutical Co., Ltd (KRX:214390)

Market Cap	145.59B -9.8%
Revenue (ttm)	252.20B +4.9%
Net Income	2.37B -51.9%
EPS	98.86 -52.1%
Shares Out	23.91M
PE Ratio	61.60
Forward PE	n/a
Dividend	50.00 (0.82%)
Ex-Dividend Date	Dec 27, 2024

Volume	55,813
Average Volume	68,233
Open	6,060.00
Previous Close	6,050.00
Day's Range	6,000.00 - 6,190.00
52-Week Range	4,755.00 - 7,160.00
Beta	0.84
RSI	55.42
Earnings Date	n/a

About Kyongbo Pharmaceutical

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE. In addition, the company is involved in CDMO business; and research an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Country: South Korea
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 214390

Financial Performance

In 2024, Kyongbo Pharmaceutical's revenue was 238.56 billion, an increase of 10.26% compared to the previous year's 216.36 billion. Earnings were 4.64 billion, an increase of 55.98%.